Shuyuan Sheng

机构：Xerox (France), J.P. Morgan, Xuzhou Construction Machinery Group (China), Second Affiliated Hospital of Zhejiang University

发表论文 7 篇 · 总被引 184 次 · h-index 3

代表论文

• Regulated cell death pathways in cardiomyopathy (2023 · Acta Pharmacologica Sinica · 被引 128)
• FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1 (2023 · Hepatology · 被引 29)
• FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1 (2025 · Circulation · 被引 23)
• Cardioprotective role of RBFox1 in myocardial infarction-induced heart failure (2025 · Cardiovascular Research · 被引 3)
• FMO2 expression confers cardioprotection in doxorubicin therapy while preserving antitumor activity (2025 · Journal of Molecular and Cellular Cardiology · 被引 1)
• Fmo2 Expression Confers Cardioprotection in Doxorubicin Therapy While Preserving Antitumor Activity (2025 · SSRN Electronic Journal)